Clinical Study
Implications of Identifying Additional Cerebral Metastases during Gamma Knife Radiosurgery
Table 1
Study population and treatment characteristics*.
| Treatment | Study cohort,
| No additional mets,
| ≥1 additional mets,
| |
| Age, years | | | | | Median | 58.7 | 57.5 | 58.8 | 0.783 | Range | 29.0–85.5 | 29.0–85.5 | 30.6–82.6 | | Sex | | | | | Male | 47 (35) | 24 (30) | 23 (43) | 0.196 | Female | 86 (65) | 55 (70) | 31 (57) | | Primary pathology | | | | | Lung | 62 (47) | 37 (47) | 25 (46) | 1.000 | Breast | 27 (20) | 16 (20) | 11 (20) | 1.000 | Melanoma | 15 (11) | 6 (8) | 9 (17) | 0.161 | Renal | 12 (9) | 9 (11) | 3 (6) | 0.359 | Other | 17 (13) | 11 (14) | 6 (11) | 0.792 | WBRT | | | | | Pre-GK-SRS | 63 (47) | 34 (43) | 29 (54) | 0.289 | Post-GK-SRS | 16 (12) | 9 (11) | 7 (13) | 0.792 | Neither | 54 (41) | 36 (46) | 18 (33) | 0.208 | Craniotomy | | | | | Yes | 34 (26) | 23 (29) | 11 (20) | 0.314 | No | 98 (74) | 56 (71) | 43 (80) | | Chemotherapy | | | | | Yes | 130 (98) | 78 (99) | 52 (96) | 0.566 | No | 3 (2) | 1 (1) | 2 (4) | | Time between scans, days | 31 (4–81) | 29 (4–81) | 37 (7–78) | 0.111 | Number of metastases | | | | | Pre-GK-SRS | 1 (1–10) | 1 (1–9) | 2 (1–10) | <0.001 | GK-SRS | 2 (1–21) | 1 (1–9) | 4 (2–21) | <0.001 | Progressive systemic disease | | | | | Yes | 69 (52) | 34 (43) | 35 (65) | 0.021 | No | 64 (48) | 45 (57) | 19 (35) | |
|
|
*Number of patients (%), unless otherwise specified.
|